WAVEMAN · COMPANY

DHR · Danaher Corp /De/

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

DHR

Name: DANAHER CORP /DE/ (DHR) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

DANAHER CORP /DE/

MEDICAL DEVICES · INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL · CIK 0000313616

CONGRESS · 1FORM 144 · 2☆ WATCH

INSIDER NET · 180D

-$13.0M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

836

13F, latest reported quarter

REVENUE GROWTH

+2.9%

XBRL, annual

NET MARGIN

14.7%

CONVERSIONS · 180D

codes C/M, not in net · $711.2K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$13.0M over 180 days

-$12.7M over 90 days

below 87% of Medical Devices

CONGRESS

1 member bought in the last year

the lowest in Medical Devices

FUNDS

836 funds added or opened last quarter

more than 96% of Medical Devices

REVENUE

+2.9% year over year

below 65% of Medical Devices

MARGIN

14.7% net margin

more than 86% of Medical Devices

BUYBACKS

$894.0M repurchased, FY to 2026-06-26

more than 93% of Medical Devices

SHORT

1.7% of shares outstanding short · 1.4 days to cover · settled 2026-07-31

below 67% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

836 funds added or opened positions in the latest 13F quarter, of 2,113 holders.

1 member of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +2.7%

+2.7%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $13.0M sold by insiders over 180 days, 836 funds added last quarter, 1 Congress member(s) bought in 12 months, $13.4M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, DANAHER CORP /DE/ insiders sold a net $13.0M of stock across 126 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Blair Rainer

President & CEO

SELL

2026-08-21

11,307.0

$2.5M

Blair Rainer

President & CEO

SELL

2026-08-21

39,193.0

$8.6M

Blair Rainer

President & CEO

SELL

2026-08-21

7,755.0

$1.7M

SPOON ALAN G

Director

SELL

2026-05-01

1,358.0

$237.2K

Milosevich Gregory M

Executive Vice President

SELL

2026-02-19

1,320.0

$274.6K

126 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 121 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

55,084,630.0 sh

$10.5B

VANGUARD CAPITAL MANAGEMENT LLC

41,377,076.0 sh

$7.9B

FMR LLC

29,540,895.0 sh

$5.6B

STATE STREET CORP

28,456,019.0 sh

$5.4B

WELLINGTON MANAGEMENT GROUP LLP

16,316,834.0 sh

$3.1B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Rainer M. Blair

FILED 2026-08-21

$12.7M

SCHWIETERS JOHN T

FILED 2026-07-14

$658.3K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Select Medical Technology and Devices Portfolio

$497.1M POSITION · AS OF 2026-02-28

13.6%

Large Cap Equity Fund

$51.2M POSITION · AS OF 2026-03-31

8.2%

Eaton Vance Atlanta Capital Focused Growth Fund

$52.8M POSITION · AS OF 2026-03-31

8.2%

VIP Health Care Portfolio

$68.3M POSITION · AS OF 2026-03-31

6.8%

Fidelity Advisor Health Care Fund

$196.0M POSITION · AS OF 2026-04-30

6.8%

Select Health Care Portfolio

$396.0M POSITION · AS OF 2026-02-28

6.4%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 6 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

1 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Government contracts

USASpending.gov · total award ceilings over the contract's life, including awards won through subsidiaries — not annual revenue

Department Of Veterans Affairs

MOLECULAR DIAGNOSTIC TESTS FOR SARS-COV-2 · 2024-03-20

$9.3M

FEDERAL AWARDS ≥ $25M IN THE LAST 90 DAYS · MATCHED VIA SAM.GOV PARENT REGISTRY

Executive pay vs shareholder return · Rainer Blair

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$23.8M

$17.3M

$9.2M

+19%

+48%

2024

$22.1M

$7.5M

$6.7M

+19%

+29%

2023

$20.9M

$5.2M

$7.1M

+19%

+26%

2022

$20.2M

$190.3K

$6.6M

+20%

+24%

2021

$17.2M

$59.5M

$6.2M

+49%

+26%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$24.6B	$23.9B	$23.9B	$26.6B
GROSS PROFIT	$14.5B	$14.2B	$14.0B	$16.2B
OPERATING INCOME	$4.7B	$4.9B	$5.2B	$7.5B
NET INCOME	$3.6B	$3.9B	$4.8B	$7.2B
EPS (DILUTED)	5.05	5.29	6.38	9.66
OPERATING CASH FLOW	$6.4B	$6.7B	$7.2B	$8.5B
LONG-TERM DEBT	$18.4B	$15.5B	$16.7B	$19.1B
BUYBACKS	$3.1B	$6.0B	$0	$0
DIVIDENDS PAID	$878.0M	$768.0M	$821.0M	$818.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE